We are analyzing https://link.springer.com/article/10.1186/s13058-015-0560-9.

Title:
Molecular characterization and targeted therapeutic approaches in breast cancer | Breast Cancer Research
Description:
Despite the wide improvements in breast cancer (BC) detection and adjuvant treatment, BC is still responsible for approximately 40,000 deaths annually in the United States. Novel biomarkers are fundamental to assist clinicians in BC detection, risk stratification, disease subtyping, prediction of treatment response, and surveillance, allowing a more tailored approach to therapy in both primary and metastatic settings. In primary BC, the development of molecular profiling techniques has added prognostic and predictive information to conventional biomarkers - estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Moreover, the application of next-generation sequencing and reverse-phase protein microarray methods in the metastatic setting holds the promise to further advance toward a personalized management of cancer. The improvement in our understanding on BC biology associated with the study of the genomic aberrations characterizing the most common molecular subtypes allows us to explore new targets for drug development. Finally, the integration of cancer stem cell-targeted therapies and immune therapies in future combination regimens increases our chances to successfully treat a larger proportion of women with more aggressive and resistant metastatic disease. This article reviews the current state of novel biological markers for BC, the evidence to demonstrate their clinical validity and utility, and the implication for therapeutic targeting.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

cancer, breast, pubmed, article, google, scholar, cells, patients, molecular, receptor, cas, gene, subtypes, clinical, tumors, central, expression, luminal, pathway, cell, treatment, signaling, tumor, clin, disease, protein, stem, tnbc, kinase, trastuzumab, pathways, including, therapy, metastatic, prognostic, phase, notch, response, growth, therapies, basallike, genes, res, trials, mutations, subtype, survival, pam, activity, resistance,

Topics {✒️}

ras/raf/mek/mapk pathway converges ras/raf/mek/mapk pathway play oestrogen-receptor-positive breast cancer triple-negative breast cancer ras/raf/mek/mapk pathways er+/her2-negative breast cancer prevalent immuno-histochemical profiles her2-negative/node-negative subgroup trastuzumab-refractory her2-positive tumors pi3k/akt/mtor pathway participates pi3k/akt/mtor pathway affect stem-cell targeted therapies ras/raf/mek/mapk breast-cancer stem cells early-stage breast cancer pten/akt/beta-catenin signaling article toss article download pdf mammary stem/progenitor cells reverse-phase protein microarray downregulating estrogen receptor-α gene-expression-based assays advancing precision medicine node-negative early bc guiding treatment decision-making multi-gene profiling tools stage ii node-positive triple-negative subtypes luminal-type/mammaprint high-risk retinoblastoma tumor-suppressor protein breast cancer based guide treatment decision-making luminal-type/mammaprint low-risk gene expression profiles extracellular-signal-regulated kinase 1/2 pi3k/akt/mtor pathway pi3k/akt/mtor pathway [19] mesenchymal-epithelial transition reverting high-risk myelodysplastic syndrome wnt/β-catenin pathway personalized cancer management advanced breast cancer extracellular domain-truncated her2 early breast cancer full size image human breast tumours metastatic er-positive bc wnt/β-catenin signaling metastatic breast cancer multi-gene assays

Questions {❓}

Targeting triple negative breast cancer: is p53 the answer?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Molecular characterization and targeted therapeutic approaches in breast cancer
         description:Despite the wide improvements in breast cancer (BC) detection and adjuvant treatment, BC is still responsible for approximately 40,000 deaths annually in the United States. Novel biomarkers are fundamental to assist clinicians in BC detection, risk stratification, disease subtyping, prediction of treatment response, and surveillance, allowing a more tailored approach to therapy in both primary and metastatic settings. In primary BC, the development of molecular profiling techniques has added prognostic and predictive information to conventional biomarkers - estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Moreover, the application of next-generation sequencing and reverse-phase protein microarray methods in the metastatic setting holds the promise to further advance toward a personalized management of cancer. The improvement in our understanding on BC biology associated with the study of the genomic aberrations characterizing the most common molecular subtypes allows us to explore new targets for drug development. Finally, the integration of cancer stem cell-targeted therapies and immune therapies in future combination regimens increases our chances to successfully treat a larger proportion of women with more aggressive and resistant metastatic disease. This article reviews the current state of novel biological markers for BC, the evidence to demonstrate their clinical validity and utility, and the implication for therapeutic targeting.
         datePublished:2015-04-23T00:00:00Z
         dateModified:2015-04-23T00:00:00Z
         pageStart:1
         pageEnd:11
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1186/s13058-015-0560-9
         keywords:
            Breast Cancer
            Trastuzumab
            Lapatinib
            Triple Negative Breast Cancer
            Recurrence Score
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13058-015-0560-9/MediaObjects/13058_2015_560_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13058-015-0560-9/MediaObjects/13058_2015_560_Fig2_HTML.gif
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:17
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Angela Toss
               affiliation:
                     name:Haematology and Respiratory Diseases, University of Modena and Reggio Emilia
                     address:
                        name:Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Massimo Cristofanilli
               affiliation:
                     name:Jefferson University Hospital
                     address:
                        name:Department of Medical Oncology, Jefferson University Hospital, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Molecular characterization and targeted therapeutic approaches in breast cancer
      description:Despite the wide improvements in breast cancer (BC) detection and adjuvant treatment, BC is still responsible for approximately 40,000 deaths annually in the United States. Novel biomarkers are fundamental to assist clinicians in BC detection, risk stratification, disease subtyping, prediction of treatment response, and surveillance, allowing a more tailored approach to therapy in both primary and metastatic settings. In primary BC, the development of molecular profiling techniques has added prognostic and predictive information to conventional biomarkers - estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Moreover, the application of next-generation sequencing and reverse-phase protein microarray methods in the metastatic setting holds the promise to further advance toward a personalized management of cancer. The improvement in our understanding on BC biology associated with the study of the genomic aberrations characterizing the most common molecular subtypes allows us to explore new targets for drug development. Finally, the integration of cancer stem cell-targeted therapies and immune therapies in future combination regimens increases our chances to successfully treat a larger proportion of women with more aggressive and resistant metastatic disease. This article reviews the current state of novel biological markers for BC, the evidence to demonstrate their clinical validity and utility, and the implication for therapeutic targeting.
      datePublished:2015-04-23T00:00:00Z
      dateModified:2015-04-23T00:00:00Z
      pageStart:1
      pageEnd:11
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1186/s13058-015-0560-9
      keywords:
         Breast Cancer
         Trastuzumab
         Lapatinib
         Triple Negative Breast Cancer
         Recurrence Score
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13058-015-0560-9/MediaObjects/13058_2015_560_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13058-015-0560-9/MediaObjects/13058_2015_560_Fig2_HTML.gif
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:17
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Angela Toss
            affiliation:
                  name:Haematology and Respiratory Diseases, University of Modena and Reggio Emilia
                  address:
                     name:Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Massimo Cristofanilli
            affiliation:
                  name:Jefferson University Hospital
                  address:
                     name:Department of Medical Oncology, Jefferson University Hospital, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:17
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Haematology and Respiratory Diseases, University of Modena and Reggio Emilia
      address:
         name:Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy
         type:PostalAddress
      name:Jefferson University Hospital
      address:
         name:Department of Medical Oncology, Jefferson University Hospital, Philadelphia, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Angela Toss
      affiliation:
            name:Haematology and Respiratory Diseases, University of Modena and Reggio Emilia
            address:
               name:Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy
               type:PostalAddress
            type:Organization
      name:Massimo Cristofanilli
      affiliation:
            name:Jefferson University Hospital
            address:
               name:Department of Medical Oncology, Jefferson University Hospital, Philadelphia, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Oncology, Haematology and Respiratory Diseases, University of Modena and Reggio Emilia, Modena, Italy
      name:Department of Medical Oncology, Jefferson University Hospital, Philadelphia, USA

External Links {🔗}(201)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.93s.

LINK . SPRINGER . COM {}